Mitochondrial DNA variants modulate N-formylmethionine, proteostasis and risk of late-onset human diseases

Nat Med. 2021 Sep;27(9):1564-1575. doi: 10.1038/s41591-021-01441-3. Epub 2021 Aug 23.

Abstract

Mitochondrial DNA (mtDNA) variants influence the risk of late-onset human diseases, but the reasons for this are poorly understood. Undertaking a hypothesis-free analysis of 5,689 blood-derived biomarkers with mtDNA variants in 16,220 healthy donors, here we show that variants defining mtDNA haplogroups Uk and H4 modulate the level of circulating N-formylmethionine (fMet), which initiates mitochondrial protein translation. In human cytoplasmic hybrid (cybrid) lines, fMet modulated both mitochondrial and cytosolic proteins on multiple levels, through transcription, post-translational modification and proteolysis by an N-degron pathway, abolishing known differences between mtDNA haplogroups. In a further 11,966 individuals, fMet levels contributed to all-cause mortality and the disease risk of several common cardiovascular disorders. Together, these findings indicate that fMet plays a key role in common age-related disease through pleiotropic effects on cell proteostasis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age of Onset
  • Biomarkers / blood*
  • Blood Donors
  • Cardiovascular Diseases / blood
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / genetics*
  • DNA, Mitochondrial / blood
  • DNA, Mitochondrial / genetics*
  • Female
  • Follow-Up Studies
  • Haplotypes / genetics
  • Humans
  • Male
  • Middle Aged
  • Mitochondria / genetics*
  • Mitochondria / pathology
  • N-Formylmethionine / metabolism
  • Proteostasis
  • Risk Factors
  • United Kingdom / epidemiology

Substances

  • Biomarkers
  • DNA, Mitochondrial
  • N-Formylmethionine